GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Net Interest Income

Albireo Pharma (FRA:BDQM) Net Interest Income : €-10.65 Mil (TTM As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Albireo Pharma's net interest income for the three months ended in Sep. 2022 was €-2.56 Mil. Its net interest income for the trailing twelve months (TTM) ended in Sep. 2022 was €-10.65 Mil.

Albireo Pharma Net Interest Income Historical Data

The historical data trend for Albireo Pharma's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Net Interest Income Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -4.25 -4.77 -9.34 -12.33

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.83 -2.88 -2.61 -2.60 -2.56

Albireo Pharma Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albireo Pharma Net Interest Income Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (FRA:BDQM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Net Interest Income
Comparable Companies
IGMS KNSA ALLO RGNX COGT QURE MRUS VKTX ARQT RAPT OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX SGEN HKSE:02269 OCSE:GMAB
Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Website
https://www.albireopharma.com
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines